Redmile Group LLC Grows Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Redmile Group LLC boosted its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 944.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 2,164,126 shares of the company’s stock after purchasing an additional 1,956,923 shares during the period. Redmile Group LLC owned approximately 3.07% of Ventyx Biosciences worth $11,903,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of VTYX. Vanguard Group Inc. raised its holdings in Ventyx Biosciences by 11.7% during the third quarter. Vanguard Group Inc. now owns 2,662,671 shares of the company’s stock worth $92,475,000 after purchasing an additional 277,906 shares in the last quarter. Opaleye Management Inc. purchased a new position in Ventyx Biosciences during the fourth quarter worth about $2,816,000. First Light Asset Management LLC purchased a new position in shares of Ventyx Biosciences during the 1st quarter worth about $3,437,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Ventyx Biosciences in the 4th quarter valued at $323,000. Finally, Simplicity Solutions LLC acquired a new position in Ventyx Biosciences in the fourth quarter valued at $81,000. 97.88% of the stock is currently owned by institutional investors and hedge funds.

Ventyx Biosciences Stock Down 22.7 %

Shares of Ventyx Biosciences stock traded down $0.67 on Monday, hitting $2.28. 4,121,144 shares of the company’s stock traded hands, compared to its average volume of 2,524,112. Ventyx Biosciences, Inc. has a 52-week low of $1.87 and a 52-week high of $38.20. The stock has a market cap of $160.74 million, a P/E ratio of -0.70 and a beta of 0.40. The firm’s 50-day moving average is $3.17 and its 200 day moving average is $4.17.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. During the same quarter in the prior year, the company earned ($0.68) EPS. Equities research analysts forecast that Ventyx Biosciences, Inc. will post -2.31 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on VTYX shares. HC Wainwright reissued a “neutral” rating and set a $6.00 price target on shares of Ventyx Biosciences in a research report on Thursday, June 13th. Oppenheimer reduced their target price on shares of Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, June 6th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.75.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.